Modulation of hypoxia in murine liver metastases of colon carcinoma by nicotinamide and carbogen.
There is increasing evidence that modulation of tumor hypoxia may improve therapy outcome. However, most preclinical data are derived from subcutaneous rather than orthotopic tumor models. We investigated the effect of the hypoxia-modulating agents nicotinamide and carbogen on tumor hypoxia, tumor blood perfusion, and proliferative activity in liver metastases of the murine colon carcinoma line C26a. In untreated C26a liver metastases, we observed a considerable amount of hypoxia, similar to the amount in liver metastases of patients with colorectal cancer. Compared to untreated mice, we observed a significantly smaller hypoxic fraction in the liver metastases of mice treated with nicotinamide and carbogen breathing as single treatments or in combination. In the group of mice that underwent carbogen breathing, perfusion was significantly lower than in the untreated group, but the decrease was only marginal. The proliferative activity was similar in all groups. In C26a subcutaneous tumors, a similar effect on hypoxia has been observed that was, however, combined with a decrease in proliferative activity. The different effects of nicotinamide and carbogen on parameters of the tumor microenvironment in liver metastases and subcutaneous tumors suggest that the host tissue influences the mechanism by which nicotinamide and carbogen exert their effects. Since tumor hypoxia may be a clinical problem in colorectal liver metastases, our results open possibilities for further research on the effect of hypoxia modifiers on colorectal liver metastases to improve therapy outcome.
van Laarhoven
H W M
HW
Department of Medical Oncology, University Medical Centre Nijmegen, 6500 HB Nijmegen, the Netherlands. h.vanlaarhoven@onco.umcn.nl
Bussink
J
J
Lok
J
J
Verhagen
I
I
Punt
C J A
CJ
Heerschap
A
A
Kaanders
J H A M
JH
van der Kogel
A J
AJ
D000818:Animals; D002245:Carbon Dioxide / Q000008:administration & dosage*; D002277:Carcinoma / Q000473:pathology* / Q000556:secondary*; D015687:Cell Hypoxia / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology*; D004338:Drug Combinations; D005260:Female; D008113:Liver Neoplasms / Q000473:pathology* / Q000556:secondary*; D051379:Mice; D008807:Mice, Inbred BALB C; D009536:Niacinamide / Q000008:administration & dosage*; D010100:Oxygen / Q000008:administration & dosage*
D004338:Drug Combinations; D002245:Carbon Dioxide; D009536:Niacinamide; C011700:carbogen; D010100:Oxygen